Historie von Umsatz, Gewinn und Cashflow aus den offiziellen Geschäftsberichten.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions.
Interaktive Charts und vollständige Abschlüsse ansehen → Bewertungsmodell (DCF) →
| Gewinn- und Verlustrechnung | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gesamtumsatz | $15.5B | $14.3B | $14.2B | $13.1B | $12.2B | $16.1B | $8.5B | $7.9B | $6.7B | $5.9B | $4.9B | $4.1B | $2.8B | $2.1B | $1.4B | $446M | $459M | $379M | $238M | $125M | $63M |
| Bruttoergebnis | $13.2B | $12.2B | $12.2B | $12.2B | $10.5B | $13.3B | $7.1B | $7.1B | $6.3B | $5.5B | $4.6B | $3.7B | $2.6B | $1.9B | $1.3B | $442M | $457M | $363M | $238M | $125M | $41M |
| Bruttomarge % | 84.9% | 85.4% | 86.1% | 93.3% | 86.0% | 83.0% | 84.0% | 90.0% | 93.5% | 93.2% | 93.8% | 90.4% | 92.7% | 92.6% | 93.9% | 99.1% | 99.5% | 95.8% | 99.6% | 100.0% | 64.2% |
| Betriebsergebnis (EBIT) | $4.0B | $3.6B | $4.0B | $4.0B | $5.4B | $8.9B | $3.6B | $2.2B | $2.5B | $2.1B | $1.3B | $1.3B | $838M | $760M | $458M | ($205M) | ($97M) | ($74M) | ($90M) | ($114M) | ($107M) |
| Operative Marge % | 25.6% | 24.9% | 28.1% | 30.9% | 44.2% | 55.7% | 42.1% | 28.1% | 37.8% | 35.4% | 27.4% | 30.5% | 29.7% | 36.1% | 33.2% | -46.0% | -21.2% | -19.5% | -37.7% | -91.5% | -169.1% |
| Jahresüberschuss | $4.3B | $4.5B | $4.4B | $4.0B | $4.3B | $8.1B | $3.5B | $2.1B | $2.4B | $1.2B | $896M | $636M | $348M | $424M | $750M | ($222M) | ($104M) | ($68M) | ($83M) | ($106M) | ($102M) |
| Nettomarge % | 27.9% | 31.4% | 31.1% | 30.1% | 35.6% | 50.2% | 41.3% | 26.9% | 36.4% | 20.4% | 18.4% | 15.5% | 12.3% | 20.2% | 54.4% | -49.7% | -22.8% | -17.9% | -34.7% | -84.5% | -161.3% |
| EBITDA | — | $5.8B | $5.3B | $4.0B | $5.3B | $9.7B | $4.1B | $2.4B | $2.7B | $2.2B | $1.4B | $1.3B | $891M | $801M | $495M | ($174M) | ($78M) | ($55M) | ($79M) | ($82M) | ($77M) |
| Ergebnis je Aktie (EPS) | $40.46 | $41.48 | $38.34 | $34.77 | $38.22 | $71.97 | $30.52 | $18.46 | $21.29 | $10.34 | $7.70 | $5.52 | $3.07 | $3.81 | $6.50 | $-2.45 | $-1.26 | $-0.85 | $-1.05 | $-1.59 | $-1.77 |
| Ausstehende Aktien (Mio.) | — | 109M | 115M | 114M | 114M | 112M | 115M | 115M | 115M | 116M | 116M | 115M | 113M | 111M | 115M | 91M | 83M | 80M | 79M | 66M | 58M |
Quelle: veröffentlichte Unternehmensberichte (SEC). Bitte prüfen Sie die Zahlen vor Verwendung auf SEC EDGAR.
Bilanzen, Cashflow-Rechnungen, Quartalsdaten und alle Kennzahlen finden Sie im interaktiven Viewer für REGN. /companies/us/REGN
Die Informationen auf dieser Website dienen ausschließlich Bildungs- und Informationszwecken und stellen keine Anlageberatung dar. Es werden keine Kursziele und keine Anlageurteile veröffentlicht.
About TickerBase · Data methodology & sources · Privacy · Terms